Oura Ring Faces Class-Action Lawsuit Over Sleep-Tracking Accuracy Claims
A class-action lawsuit filed against Oura alleges the company misled consumers by marketing its smart ring as capable of accurately tracking sleep stages when, according to the complaint, the device's accuracy is roughly equivalent to a coin flip.
The complaint, Surber v. Oura Inc. et al. (case number 26-cv-08686), was filed by Clarkson Law Firm on behalf of named plaintiff Madison Surber, who purchased an Oura Ring 4 Gold around May 22, 2025. News of the filing was widely reported on August 21, 2026, with subsequent coverage from The Verge's Optimizer newsletter and ClassAction.org providing additional detail through August 26 (Mashable, The Verge, ClassAction.org).
At the core of the dispute is a fundamental limitation of wrist- and finger-based wearables: they cannot directly measure brain activity. The lawsuit contends that because a smart ring lacks EEG sensors, it cannot accurately track sleep stages, which are defined by distinct brain-wave patterns. Instead, Oura relies on AI-driven inference models that extrapolate sleep architecture from peripheral signals like heart rate variability, body temperature, and movement. The complaint characterizes these models as taking advantage of "desperate consumers who struggle with their sleep" by selling faulty AI-based inference as reliable science (The Verge).
The gap between marketed and actual performance is central to the plaintiffs' case. Oura advertised its ring as measuring different sleep stages with 95% accuracy. Clarkson Law Firm attorney Shireen Clarkson stated that Oura's own internal estimates of sleep-stage tracking accuracy are closer to 50%. The complaint cites peer-reviewed, independent scientific studies showing Oura rings are roughly 50 percent accurate at sleep tracking, which the lawsuit describes as no better than a "coin flip" (USA Today, The Verge, ClassAction.org).
Oura has pushed back. The company published a rebuttal linking to peer-reviewed validation studies for its sleep tracking algorithm, accompanied by a supportive op-ed from a sleep researcher. Oura's response frames its methodology as scientifically grounded and independently verified (The Verge).
The broader context here is the tension between consumer-grade biosensor marketing and the technical reality of indirect physiological measurement. Sleep staging via polysomnography, the gold-standard clinical sleep study, requires EEG (brain activity), EOG (eye movement), and EMG (muscle activity) data. Consumer wearables approximate these signals through photoplethysmography, which uses light to measure blood flow, along with accelerometry and temperature sensing. They then apply machine-learning models trained on clinical data. The output is probabilistic inference, not direct measurement. When a wearable claims 95% accuracy for sleep staging, that figure typically reflects agreement with polysomnography under controlled validation conditions, not the device's standalone reliability in a consumer's bedroom.
The lawsuit's framing of AI-based inference as inherently suspect is worth flagging. Inference is the mechanism by which all consumer wearables produce sleep-stage estimates. The question is not whether inference is used but whether the accuracy claims are substantiated and honestly communicated. The distinction between a model that achieves 95% concordance with polysomnography in a validation study and one that performs at 50% in the field is the difference between a useful consumer tool and an expensive random number generator. Whether Oura's devices fall into the former or latter category, and whether its marketing crossed the line from optimistic to deceptive, is what the court will weigh.
What remains genuinely useful about consumer sleep wearables, even at less-than-clinical accuracy, is trend tracking. A device that is 50% accurate at classifying a given night's sleep stage may still capture longitudinal shifts in total sleep time, resting heart rate, and nighttime movement that correlate with real physiological changes. The risk, though, is that when consumers receive specific stage labels presented with false precision, they may make health decisions based on data that is, in the lawsuit's characterization, a coin flip. That is the core issue the court will be asked to resolve.
